20409 ⎘
Medicinal preparations containing organic active ingredients; Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring heteroatoms, e.g. piperazine Non-condensed pyrazines
Sub-classes:BCMA VH-ONLY CARS
#2Use of Tetramethylpyrazine Nitrone Derivatives In The Treatment of Ischemic Stroke
#3HUMAN ANTIBODY AGAINST CORONAVIRUS VARIANTS OR ANTIGEN-BINDING FRAGMENT THEREOF
#4NOVEL COMPOUNDS AND USES THEREOF
#5LIPOSOME FORMULATIONS FOR TREATMENT OF ACTIVE TUBERCULOSIS
#6HETEROARYL COMPOUNDS AS MULTI-TARGET PROTEIN KINASE INHIBITORS
#7NOVEL HETEROBICYCLIC COMPOUND FOR INHIBITING YAP-TEAD INTERACTION AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
#8CYSTEAMINE FOR THE TREATMENT, MITIGATION AND PREVENTION OF CORONAVIRAL, E.G., SARS-CoV-2, INFECTIONS
#9NOVEL COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF
#10ARTEMISINIC ACID DERIVATIVE, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
#11COMBINATION TREATMENTS
#12Compounds with Anti-Acinetobacter Baumannii Activity
#13PROSTANOID RECEPTOR AGONISTS AS NON-TUBERCULOUS ANTI-MYCOBACTERIAL AGENTS
#14CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION OF SELEXIPAG OR IT'S ACTIVE METABOLITE
#15METHOD FOR DETECTING OR TREATING TRIPLE NEGATIVE BREAST CANCER
#16ALPHA-KETOGLUTARATE (AKG)-BASED POLYMERIC MICROPARTICLES AND METHODS OF USE
#17ANALOGUES OF PENTAMIDINE AND USES THEREFOR
#18COMPOUNDS AND THEIR USES AS CD38 INHIBITORS
#19Phenotype-Based Chemical Screens
#20IDENTIFICATION AND USE OF SHP2 CONFORMATIONAL DISRUPTORS FOR CANCER TREATMENT
#21NOVEL MOLECULES
#22INHIBITING ATAXIA TELANGIECTASIA AND RAD3-RELATED PROTEIN (ATR)
#23INHIBITING PURINE BIOSYNTHESIS TO INCREASE FAVIPIRAVIR POTENCY AGAINST RNA VIRUS INFECTIONS
#24PYRUVATE KINASE ACTIVATORS FOR USE IN THERAPY
#25METHODS OF TREATMENT FOR CYSTIC FIBROSIS
#26ALPHA 4 BETA 7 INTEGRIN MODULATORS AND USES THEREOF
#27FLT COMBINATION THERAPY FOR CANCER AND COMPOSITIONS THEREFOR
#28HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME
#29METHODS FOR THE TREATMENT OF DEPRESSION
#30NOVEL BENZENE DERIVATIVE AND IMMUNOSUPPRESSION-RELATED USE THEREOF
#31PLPRO PROTEIN INHIBITOR, AND PREPARATION METHOD AND APPLICATION THEREOF
#32BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES
#33PYRIDINE DERIVATIVES FOR TREATING PSYCHIATRIC DISORDERS
#34MODIFIED CAVEOLIN-1 PEPTIDES FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE
#35CALMODULIN INHIBITORS FOR THE TREATMENT OF RIBOSOMAL DISORDERS AND RIBOSOMOPATHIES
#36POLYAMIDE COMPOUNDS, METHOD FOR PREPARING SAME, AND MEDICAL USE THEREOF
#37INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE
#38TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA
#39PULMONARY HYPERTENSION TREATMENT
#40ADJUNCTIVE TREATMENT OF MYCOBACTERIAL DISEASES
#41ALLOSTERIC INHIBITORS OF THE MAIN PROTEASE OF SARS-COV-2
#42NOVEL B0AT1 INHIBITOR
#43AMILORIDE FOR USE IN THE TOPICAL TREATMENT OF SOMATOSENSORY IMPAIRMENTS
#44SULFONYLUREA COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF
#45COMPOSITE PARTICLE FORMULATIONS AND APPLICATIONS THEREOF
#46PYRAZINE COMPOUNDS AS IRREVERSIBLE INHIBITORS OF FLT3
#47PLANT-DERIVED SMALL MOLECULES AS MARBURG VIRUS INHIBITORS
#48USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK)
#49CANCER IMMUNOTHERAPY COMPOSITION CONTAINING INTERACTION INHIBITOR OF STING AND TRIM29 AS ACTIVE INGREDIENT
#50METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION INJURY IN THE LUNGS
#51SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS
#52BIPHENYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS
#53BICYCLIC-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS
#54USE OF ANTI-IDIOPATHIC PULMONARY FIBROSIS DRUG NINTEDANIB IN TREATMENT OF TUBERCULOSIS
#55TRANSDERMAL THERAPEUTIC SYSTEM FOR THE TRANSDERMAL ADMINISTRATION OF SELEXIPAG
#56CELL-PERMEANT INHIBITORS OF VIRAL CYSTEINE PROTEASES
#57N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTI-VIRAL USES RELATED THERETO
#58KETOAMIDE DERIVATIVES AND PHARMACEUTICAL USES THEREOF
#59NOVEL IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND METHODS OF USING THE SAME
#60WILLOW EXTRACT AND ITS USE IN TREATING A VIRAL INFECTION, ALLERGIC REACTION, AND OTHER MEDICAL CONDITIONS
#61AMINE COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC, AND ANTICANCER ACTIVITY
#62POLYMERSOME NANOPARTICLES EXHAUSTING INTRACELLUAR AMINO ACID FOR CANCER THERAPY AND METHODS THEREOF
#63METHOD OF CARDIOPROTECTION
#64Magnetic nano-drug with double targeting VEGF-VEGFR, and preparation method and application thereof
#65ADHESIVE PATCH CONTAINING SELEXIPAG AS ACTIVE INGREDIENT
#66RXFP1 AGONISTS
#67METHOD OF TREATING A SKIN DISORDER
#68MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
#69NEW SALT FORMS OF AMILORIDE AND ITS DERIVATIVES FOR PHARMACEUTICAL USE
#70Substituted Monohydrazides as Potent Antifungal Agents
#71PROCESS FOR MANUFACTURING A DIPHENYLPHRAZINE DERIVATIVE
#72HETEROARYL DERIVATIVE PARP INHIBITOR AND USE THEREOF
#73SOS1 INHIBITOR AND USE THEREOF
#74COMPOSITION AND METHOD OF TREATING BRAIN CANCER
#75EPITHELIAL SODIUM CHANNEL (ENAC) INHIBITOR CONJUGATES AND METHODS FOR USE THEREOF
#76ANTICOAGULANT REVERSAL AGENTS
#77Antigen Binding Molecules Targeting SARS-CoV-2
#78PYRAZINE COMPOUND, AND METHOD OF PREPARATION AND USE THEREOF
#79Covalent Inhibitors As Antiviral Agents
#80COMBINATION THERAPY
#81THERAPEUTIC AGENT FOR COVID-19
#82COMPOSITIONS AND METHODS FOR INHIBITING PLpro PROTEASE ACTIVITY AND FOR PREVENTING AND TREATING SARS-CoV-2 INFECTION
#83DRAK2 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF
#84MODULATORS OF THE INTEGRATED STRESS PATHWAY
#85METHODS AND DEVICES FOR MODULATING ELECTROLYTE EXCRETION
#86PYRUVATE KINASE ACTIVATORS FOR USE IN THERAPY
#87COMPOUNDS AND THEIR USES AS CD38 INHIBITORS
#88Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha
#89FATTY ACID AMIDE HYDROLASE (FAAH) CLEAVABLE PRODRUGS OF THYROMIMETICS AND COMBINATION WITH PERIPHERALLY RESTRICTED FAAH INHIBITORS
#90AGENT FOR TREATING INFECTIOUS DISEASES AGAINST MUTANT VIRUSES OF NOVEL CORONAVIRUS
#91INHIBITORS OF UBIQUITIN SPECIFIC PEPTIDASE 22 (USP22) AND USES THEREOF FOR TREATING DISEASE AND DISORDERS
#92METHODS AND USES OF PROTEIN DISULFIDE ISOMERASE INHIBITORY COMPOUNDS
#93TRPM8 AGONISTS AS COOLING AGENTS AND FOR THE TREATMENT OF DISEASE
#94Inhibitors of receptor interacting protein kinase I for the treatment of disease
#95THERAPEUTIC AGENT FOR GAIT DISTURBANCE
#96THERAPEUTIC AGENT FOR CORONAVIRUS INFECTION
#97ANTI-CANCER COMPOUNDS
#98FIBER SUPPLEMENTATION PROTECTS FROM ANTIBIOTIC-INDUCED GUT MICROBIOME DYSBIOSIS BY MODULATING REDOX METABOLISM
#99USE OF KAPPA OPIOID RECEPTOR AGONISTS TO TREAT CARDIOVASCULAR DISEASE
#100METHODS OF USING EHMT2 INHIBITORS IN TREATING OR PREVENTING BLOOD DISORDERS
#101MODULATORS OF THE INTEGRATED STRESS PATHWAY
#102ANTI-MYCOBACTERIAL DRUGS
#103MYCOBACTERIUM TUBERCULOSIS COMPOSITIONS AND METHODS
#104METHODS FOR TREATING PULMONARY HYPERTENSION
#105PHARMACEUTICAL COMPOSITIONS COMPRISING SORBITAN ESTERS
#106AMINONAPHTHOQUINONE COMPOUNDS FOR TREATMENT AND/OR PREVENTION OF FIBROSIS DISEASES
#107Diketopiperazine Salts for Drug Delivery and Related Methods
#108AN INHALABLE DRY POWDER COMPOSITION FOR PULMONARY DISEASES
#109Calmodulin inhibitors for the treatment of ribosomal disorders and ribosomopathies
#110DRUGS, THERAPEUTIC COMBINATIONS AND METHODS FOR PREVENTING VIRAL AND MICROBIAL INFECTIONS AND THEIR SEQUELAE
#111Pharmaceutical Compositions Comprising Sorbitan Esters
#112Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis
#113Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors
#114PHARMACEUTICAL COMPOSITION
#115PHARMACEUTICAL COMPOSITION
#116A CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION OF SELEXIPAG OR IT'S ACTIVE METABOLITE
#117THERAPEUTIC COMBINATIONS COMPRISING A CRAF INHIBITOR
#118USE OF AN ERK INHIBITOR FOR THE TREATMENT OF MYELOFIBROSIS
#119Anti-mycobacterial drugs
#120INHIBITING ATAXIA TELANGIECTASIA AND RAD3-RELATED PROTEIN (ATR)
#121Combination Antibacterial Composition and Short-Course Antibacterial Regimen
#122USE OF ATR AND CHK1 INHIBITOR COMPOUNDS
#123MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
#124LYOTROPIC LIQUID CRYSTALLINE PHASE PARTICLE
#125SPRAY-DRIED METAL-ORGANIC FRAMEWORKS FOR TREATMENT AND/OR DIAGNOSIS OF PULMONARY DISEASE
#126CONJUGATES OF ACTIVE PHARMACEUTICAL INGREDIENTS
#127ANTIVIRAL AGENT FOR COMBINED THERAPY OF COVID-19 (SARS-COV-2)
#128COMPOSITIONS AND METHODS UTILIZING PROTEIN INHIBITORS FOR SYNERGISTIC INHIBITION AND TREATMENT OF SARS-CoV-2
#129USE OF AN ERK INHIBITOR FOR THE TREATMENT OF MYELOFIBROSIS
#130Lithium oxyhalide electrochemical cell design for high-rate discharge
#131Antigen Binding Molecules Targeting SARS-CoV-2
#132Antigen binding molecules targeting SARS-CoV-2
#133USE OF ACTIVE SUBSTANCES WITH ANTIVIRAL, ANTI MALARIAL, AND/OR MUCOLYTIC PROPERTIES IN THE TREATMENT OF VIRAL LUNG DISEASES INCLUDING COVID-19 BY SOFT MIST INHALER OR VIBRATION MESH TECHNOLOGY NEBULIZER THROUGH INHALATION ROUTE
#134COMBINATION OF A PROTEASOME INHIBITOR AND A HDAC INHIBITOR AND ITS USE FOR THE TREATMENT OF GENETIC DISEASES LINKED TO A PROTEIN CONFORMATIONAL DISORDER
#135INHIBITORS OF ACID SPHINGOMYELINASE FOR PREVENTING AND TREATING THE COVID-19 DISEASE
#136ANTI-RNA VIRAL PHARMACEUTICAL COMBINATION THERAPY WITH APROTININ + anti-RNA DRUG
#137MOLECULES FOR USE IN THE TREATMENT OF VIRAL INFECTIONS
#138COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS
#139FORMULATIONS AND METHODS FOR TREATMENT OF FIBROMYALGIA AND RELATED MYOFASCIAL PAIN DISORDERS
#140COMPOSITIONS AND METHODS FOR HAIR FOLLICLE REGENERATION
#141Identification of inhibitors of TcpC and TIR NADase activity
#142Carboxylic acid aromatic amides as antagonists of bradykinin B1 receptor
#143EXPANDED MEMORY SUBSETS OF GAMMA DELTA T CELLS FOR IMMUNOTHERAPY
#144METHOD FOR DETECTING OR TREATING TRIPLE NEGATIVE BREAST CANCER
#145PARTIALLY DESULFATED HEPARIN FOR TREATING CORONAVIRAL INFECTIONS
#146NOVEL DRUG-CONTROLLED SYSTEMS AND USES THEREOF
#147DIMETHYL SULFOXIDE (DMSO) AND METHYLSULFONYLMETHANE (MSM) FORMULATIONS TO TREAT OSTEOARTHRITIS
#148Cysteine protease inhibitors and methods of use thereof
#149ECLITASERTIB FOR USE IN TREATING CONDITIONS INVOLVING SYSTEMIC HYPERINFLAMMATORY RESPONSE
#150MODIFIED CAVEOLIN-1 PEPTIDES FOR THE TREATMENT OF PATHOGEN-INDUCED LUNG INJURY
#151MEDICAMENT FOR TREATING HYPERTENSION
#152DRUG AND DIAGNOSTIC COMBINATION SYSTEM TO IDENTIFY AND TREAT SINGLE-STRANDED RNA VIRUSES INCLUDING CORONAVIRUSES AND MONKEYPOX
#153CORONAVIRUS INFECTION THERAPEUTIC AGENT FORMED THROUGH COMBINATION OF PYRAZINE DERIVATIVE AND ANOTHER CORONAVIRUS INFECTION THERAPEUTIC DRUG
#154THERAPEUTIC AGENT FOR AN RNA VIRUS INFECTION COMPRISING A COMBINATION OF A PYRAZINE DERIVATIVE AND A THIOPURINE DERIVATIVE
#155SARS-CoV-2 Antiviral Pharmaceutical Composition and Application Thereof
#156Method for treating RNA viral infections, including COVID-19 (SARS-CoV-2)
#157SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME
#158Treatment of aneurysms
#1596-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING DISEASES AND CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY
#160METHODS TO PREVENT, AMELIORATE AND TREAT COMPLICATIONS FROM VIRAL INFECTIONS
#161Anti-RNA virus, including anti-SARS-CoV-2 virus, pharmaceutical composition Avifavir
#162THERAPEUTIC AGENT FOR CORONAVIRUS INFECTION
#163MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
#164USES OF TAXIFOLIN FOR RESPIRATORY HEALTH
#165COMPOSITIONS AND METHODS FOR THE TREATMENT OF INTRACELLULAR BACTERIAL INFECTIONS
#166IMIDAZOLYL THIOPEHENE SULFONYL CARBAMATES FOR USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH ANGIOTENSIN II
#167CONTROLLED RELEASE SELEXIPAG COMPOSITION
#168COBICISTAT FOR PREVENTION AND/OR TREATMENT OF CORONAVIRUS INFECTIONS
#169COMPOSITIONS AND METHODS FOR THE TREATMENT OF INTRACELLULAR BACTERIAL INFECTIONS
#170METHOD FOR TREATING CANCER USING A COMBINATION OF DNA DAMAGING AGENTS AND ATR INHIBITORS
#171A TRIPLE PHARMACEUTICAL COMBINATION COMPRISING DABRAFENIB, AN ERK INHIBITOR AND A SHP2 INHIBITOR
#172Use of sodium dichloroisocyanurate (NaDCC) and a pharmaceutical formulation prepared therefrom
#173METHODS OF TREATING AND ASSESSING PULMONARY ARTERIAL HYPERTENSION WITH SELEXIPAG
#174ANTISENSE NUCLEIC ACID THAT INDUCES SKIPPING OF EXON 50
#175Carboxylic acid aromatic amides
#176METHODS OF TREATING PULMONARY ARTERIAL HYPERTENSION
#177Anti-cancer compounds
#178MrgprX2 Antagonists and Uses Thereof
#179Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha
#180Pharmaceutical Composition For The Treatment Of Pulmonary Arterial Hypertension
#181SODIUM-GLUCOSE LINKED TRANSPORTER INHIBITORS FOR THE MANAGEMENT OF CHRONIC KIDNEY DISEASE, HYPERTENSION, AND HEART FAILURE IN COMPANION ANIMALS
#182POLYPEPTIDE, AND PREPARATION METHOD THEREFOR AND USE THEREOF
#183Inhalable antimicrobial particles and methods of making the same
#184USE OF MEMBRANE INHIBITORS TO ENHANCE VACCINE DEVELOPMENT AGAINST ENVELOPED VIRUSES
#185PHARMACEUTICAL COMPOSITION COMPRISING SELEXIPAG
#186EP2 ANTAGONIST
#187Compositions of Clofazimine, Combinations Comprising Them, Processes for Their Preparation, Uses and Methods of Treatment Comprising Them
#188THREE-DIMENSIONAL MICROFLUIDICS DEVICES FOR THE DELIVERY OF ACTIVES
#189COMBINATION TREATMENTS
#190Antisense nucleic acid that induces skipping of exon 50
#191Substituted bicyclic compounds
#192METHODS FOR TREATING SARCOIDOSIS-ASSOCIATED PULMONARY HYPERTENSION
#193METHODS OF MONITORING MUCOSAL HEALING
#194Willow extract and its use in treating a viral infection, allergic reaction, and other medical conditions
#195METHODS FOR TREATING PULMONARY ARTERIAL HYPERTENSION
#196MEDICAMENT AND FOOD FOR PREVENTING OR TREATING NOVEL CORONAVIRUS PNEUMONIA COVID-19 AND USE THEREOF
#197ANTI-CANCER COMPOSITIONS AND METHODS OF USE
#198POTENTIATION OF ANTIVIRAL NUCLEOBASES AS RNA VIRUS THERAPY
#199BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES
#200TRANSITIONING PATIENTS TREATED FOR PULMONARY ARTERIAL HYPERTENSION TO SELEXIPAG
#201METHOD FOR TREATING CANCER USING A COMBINATION OF CHK1 AND ATR INHIBITORS
#202Pulmonary hypertension treatment
#203COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE AND COMBINATION THERAPIES THEREOF
#204COMBINATION THERAPY FOR TREATING CANCER
#205COMBINATION GMCI AND ATRI CANCER TREATMENT
#206Methods for Detecting A Mycobacterium Tuberculosis Infection
#207Use of ligustrazine nitrone derivatives in treatment and prevention of diabetic complication diseases
#208METHOD OF TREATMENT OF ACTINIC KERATOSES
#209Treatment of ischemia
#210PHARMACEUTICAL COMPOSITION COMPRISING TBN, OR SALT OR HYDRATE THEREOF, AND PREPARATION METHOD THEREOF
#211SMALL-MOLECULE INHIBITOR OF PD-1/PD-L1, PHARMACEUTICAL COMPOSITION THEREOF WITH PD-L1 ANTIBODY, AND APPLICATION OF SAME
#212COMPOSITIONS AND METHODS FOR RADIOTHERAPY USING CHELATED RADIOTHERAPEUTIC AGENTS AND NON-TARGET TISSUE BLOCKADE
#213Calmodulin inhibitors for the treatment of ribosomal disorders and ribosomapathies
#214FLUORESCENT PYRAZINE DERIVATIVES AND METHODS OF USING THE SAME IN ASSESSING RENAL FUNCTION
#215THIENO[2,3-D)PYRIMIDINES AND BENZOFURO(3,2-D)PYRIMIDINES AS ANTIMICROBIAL AGENTS
#216Pharmaceutical composition for the treatment of pulmonary arterial hypertension
#217Therapeutic agent for RNA viral infection comprising a combination of pyrazine derivative and compound which increases amount of pyrazine derivative ribose triphosphate in cell
#218PZA and cytochrome Bc1 inhibitor combination treatment
#219FARNESOID X RECEPTOR AGONISTS AND USES THEREOF
#220PHARMACEUTICAL COMPOSITION CONTAINING AMLODIPINE, CHLORTHALIDONE, AND AMILORIDE AND APPLICATION THEREOF
#221METHODS AND COMPOSITIONS FOR MODULATING IMMUNE DYSREGULATION
#222Drug-controlled systems and uses thereof
#223METHODS FOR TREATING INFECTIOUS DISEASES
#224Composition and methods for preventing or reducing the incidence of transient ischemic attacks
#225METHODS OF INHIBITING PROCOLLAGEN-LYSINE, 2-OXOGLUTARATE 5-DIOXYGENASE 2
#226Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
#227Synthetic Antibacterial Compounds and Uses Thereof
#228Therapeutic combinations comprising a c-RAF inhibitor
#229Cysteamine for the Treatment, Mitigation and Prevention of Coronaviral, e.g., SARS-CoV-2, Infections
#230PKC-Delta-I inhibitor formulations and uses thereof
#231[1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors
#232MODULATORS OF THE INTEGRATED STRESS PATHWAY
#233Uses of Electron Transport Chain Complex I or Complex II Inhibitors in Treating Cancer, Combination Therapies, and Diagnostic Methods Related Thereto
#234COMPOSITIONS AND METHODS FOR SUPPRESSING MSUT2
#235METHODS OF TREATING DISEASES AND DISORDERS RESULTING FROM BETA CORONAVIRUS INFECTION
#236USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK)
#237Method of treating severe acute respiratory syndrome (SARS) virus infection by administering a protein disulfide isomerase (PDI) inhibitor
#238Use of Favipiravir in treatment of coronavirus infection
#239LIPID-COATED PARTICLES FOR TREATING VIRAL INFECTIONS
#240Use of Trimetazidine in Preparation of Drugs for Preventing and Treating Liver Diseases
#241Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2α
#242Inhibiting ataxia telangiectasia and RAD3-related protein (ATR)
#243METHODS OF TREATING VIRAL INFECTIONS USING INHIBITORS OF NUCLEOTIDE SYNTHESIS PATHWAYS
#244ACC INHIBITORS FOR USE IN TREATING MYCOBACTERIAL DISEASES
#245Ophthalmic formulations of cetirizine and methods of use
#246Method for treatment of a viral-mediated infectious disease
#247Hetero-halo inhibitors of histone deacetylase
#248Composition for ameliorating peripheral sensory neuropathy
#249MODULATORS OF THE INTEGRATED STRESS PATHWAY
#250Substituted oxazolidinones for the treatment of mammalian infections
#251TOPICAL FORMULATIONS OF DGAT1 INHIBITORS AND THEIR METHODS OF USE
#252METHODS OF USING EHMT2 INHIBITORS IN TREATING OR PREVENTING BLOOD DISORDERS
#253N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTI-VIRAL USES RELATED THERETO
#254Pyridine and pyrazine derivative for the treatment of chronic bronchitis
#255Mitochondrial Conductance Inhibitors and Methods of Use Thereof
#256Composition for reducing nervous system injury and method of making and use thereof
#257USE OF FAVIPIRAVIR IN TREATMENT OF CORONAVIRUS INFECTION
#258Pyruvate kinase activators for use in therapy
#259NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN
#260Use of prostacyclin antagonists for treating ocular surface nociception
#261Substituted 6-membered aryl or heteroaryl allosteric modulators of nicotinic acetylcholine receptors
#262Pharmaceutical composition for the treatment of pulmonary arterial hypertension
#263AZA-PYRIDONE COMPOUNDS AND USES THEREOF
#264MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE
#265Compositions and methods for delivering pharmaceutical agents
#266THIOACETATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE
#267ANTICOAGULANT REVERSAL AGENTS
#268Imidazoquinolyl compounds having anti-inflammatory, antifungal, antiparasitic, and anticancer activity
#269COMPOSITIONS AND METHODS FOR TREATMENT OF IRON OVERLOAD
#270Methods of treatment of cancer
#271SHP2 INHIBITOR COMPOSITIONS AND METHODS FOR TREATING CANCER
#272Conjugates of active pharmaceutical ingredients
#273Diketopiperazine salts for drug delivery and related methods
#274METHODS OF TREATING MINIMAL RESIDUAL CANCER
#275METHOD OF TREATING EPILEPSY OR EPILEPTIC ENCEPHALOPATHY WITH FENFLURAMINE IN PATIENTS WITHOUT PULMONARY HYPERTENSION
#276RAR selective agonists in combination with immune modulators for cancer immunotherapy
#277Inhibitors of receptor interacting protein kinase I for the treatment of disease
#278Polycyclic carbamoylpyridone derivatives, pharmaceutical compositions and use thereof
#279Substituted 6-membered aryl or heteroaryl allosteric modulators of nicotinic acetylcholine receptors
#280Stable pharmaceutical composition of Selexipag
#281Method for producing freeze-dried formulation
#282NOVEL GLUTAMINASE INHIBITORS
#283Farnesoid X receptor agonists and uses thereof
#284Methods, compositions, and uses of novel FYN kinase inhibitors
#2853,5-diamino-6-chloro-N-(N-(4-(4-(2-(hexyl(2,3,4,5,6-pentahydroxyhexyl)amino)ethoxy)phenyl)butyl)carbamimidoyl)pyrazine-2-carboxamide
#286Lithium oxyhalide electrochemical cell design for high-rate discharge
#287REDUCING CUTANEOUS SCAR FORMATION AND TREATING SKIN CONDITIONS
#288FORMULATIONS OF AZAINDOLE COMPOUNDS
#289Ophthalmic formulations of cetirizine and methods of use
#290Inhibiting ataxia telangiectasia and Rad3-related protein (ATR)
#291GRANULAR COMPOSITION, PRODUCTION METHOD FOR GRANULAR COMPOSITION, AND DISSOLUTION PROPERTY IMPROVEMENT METHOD FOR GRANULAR COMPOSITION
#292TREATING CANCER WITH ATR INHIBITORS
#293Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis
#294MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
#295Pulmonary hypertension treatment
#296THERAPIES FOR HEMATOLOGIC MALIGNANCIES
#297Process for the preparation of diphenylpyrazine derivatives
#298Controlled-release preparation
#299Treatment of ischemia
#300Compounds and compositions for inhibition of FASN